
HER2-mutant Non-Small Cell Lung Cancer- Pipeline Insight, 2024
Description
HER2-mutant Non-Small Cell Lung Cancer- Pipeline Insight, 2024
DelveInsight’s, “HER2-mutant Non-Small Cell Lung Cancer- Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in HER2-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
HER2-mutant Non-Small Cell Lung Cancer: Overview
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancers. NSCLC is one of the most genomically diverse cancers, making it very difficult to treat. For all NSCLC patients who have the adenocarcinoma subtype, testing for alterations in epidermal growth factor receptor (EGFR), mesenchymal epithelial transition factor (MET), b-raf proto-oncogene (BRAF), anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), ret proto-oncogene (RET) and neurotrophic tyrosine receptor kinase (NTRK) is recommended by the National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) guidelines. Non-small-cell lung cancer (NSCLC) harbouring HER2 alterations is now considered a distinct molecular subtype. The activation of HER2 in NSCLC occurs via three mechanisms, i.e. gene mutation (1%-4% of cases), gene amplification (2%-5%) and protein overexpression (2%-30%), with different prognostic and predictive outcomes. Lung cancer is the leading cause of cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC), the main histologic subtype accounting for 85% of lung cancer cases, is a heterogeneous disease driven by a wide spectrum of molecular alterations. One might notice symptoms in the early stages. Or might mistake them for another illness, such as pneumonia or a collapsed lung. Like other types of lung cancer, symptoms can include: Coughing that lasts or gets worse, chest pain that often hurts more when coughs, laugh, or take deep breaths, hoarseness or voice changes, harsh, raspy sounds when a person breathes, wheezing, weight loss and little appetite. Tests and procedures to diagnose and stage non-small cell lung cancer are often done at the same time. Some of the following tests and procedures may be used: Physical exam and health history: An exam of the body to check general signs of health, including checking for signs of disease, such as lumps or anything else that seems unusual. A history of the patient’s health habits, including smoking, and past jobs, illnesses, and treatments will also be taken, laboratory tests: medical procedures that test samples of tissue, blood, urine, or other substances in the body. These tests help to diagnose disease, plan and check treatment, or monitor the disease over time, chest x-ray: An x-ray of the organs and bones inside the chest. An x-ray is a type of energy beam that can go through the body and onto film, making a picture of areas inside the body.
""HER2-mutant Non-Small Cell Lung Cancer- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the HER2-mutant Non-Small Cell Lung Cancer pipeline landscape is provided which includes the disease overview and HER2-mutant Non-Small Cell Lung Cancer treatment guidelines. The assessment part of the report embraces, in depth HER2-mutant Non-Small Cell Lung Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HER2-mutant Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence HER2-mutant Non-Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve HER2-mutant Non-Small Cell Lung Cancer.
This segment of the HER2-mutant Non-Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
HER2-mutant Non-Small Cell Lung Cancer Emerging Drugs
- DZD-9008: Dizal Pharmaceuticals
- Enhertu: AstraZeneca
- Pyrotinib: Jiangsu Hengrui Medicine
Further product details are provided in the report……..
HER2-mutant Non-Small Cell Lung Cancer: Therapeutic Assessment
This segment of the report provides insights about the different HER2-mutant Non-Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in HER2-mutant Non-Small Cell Lung Cancer
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
HER2-mutant Non-Small Cell Lung Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses HER2-mutant Non-Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HER2-mutant Non-Small Cell Lung Cancer drugs.
HER2-mutant Non-Small Cell Lung Cancer Report Insights
- HER2-mutant Non-Small Cell Lung Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing HER2-mutant Non-Small Cell Lung Cancer drugs?
- How many HER2-mutant Non-Small Cell Lung Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of HER2-mutant Non-Small Cell Lung Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the HER2-mutant Non-Small Cell Lung Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for HER2-mutant Non-Small Cell Lung Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Dizal Pharmaceuticals
- Puma Biotechnology
- AstraZeneca
- Jiangsu Hengrui Medicine
- Spectrum Pharmaceuticals, Inc.
- DZD-9008
- Neratinib
- Enhertu
- Pyrotinib
- Poziotinib
Table of Contents
60 Pages
- Introduction
- Executive Summary
- HER2-mutant Non-Small Cell Lung Cancer: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- HER2-mutant Non-Small Cell Lung Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- Comparative Analysis
- Enhertu: AstraZeneca
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- DZD-9008: Dizal Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- HER2-mutant Non-Small Cell Lung Cancer Key Companies
- HER2-mutant Non-Small Cell Lung Cancer Key Products
- HER2-mutant Non-Small Cell Lung Cancer- Unmet Needs
- HER2-mutant Non-Small Cell Lung Cancer- Market Drivers and Barriers
- HER2-mutant Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
- HER2-mutant Non-Small Cell Lung Cancer Analyst Views
- HER2-mutant Non-Small Cell Lung Cancer Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.